65,437 trials
Pneumonia, Bacterial · Healthy Volunteers · Pneumococcal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), [Stage 1, Group 1] — 11; 5; 5; 5 Participants
Recurrent Malignant Solid Neoplasm · Recurrent Melanoma · Recurrent Primary Central Nervous System Neoplasm
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose of Cabozantinib S-malate — 40 mg/m^2
Gaucher Disease
Primary: Number of Participants With Clinically Stable Hemoglobin (Hb) Concentration From Baseline up to Month 12 — 2; 2 Participants
Spinal Cord Injuries · Inpatient
Primary: Change in Spinal Cord Independence Measure (SCIM) Version III Scores — 18.6; 27.0; 54.5; 50.0 score on a scale — p=<0.01
Thoracic Procedure · Urologic Procedure · Ear, Nose and Throat Procedure
Primary: Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale — 108 vessels transected
Stress Urinary Incontinence · Pelvic Floor; Weak · Incontinence, Urinary
Primary: Change in Quality of Life — 4.73; 3.95 score on a scale
Gestational Diabetes
Primary: Number of Participants Assessed for Glucose Control — 50; 50 Participants
SARS CoV-2
Primary: C-reactive Protein — -3.6; -5.5 mg/dL
Blepharitis
Primary: Proportion of Participants Cured Based on a Collarette Score at Day 43. — 0.439; 0.072 Proportion cured
Healthy
Primary: Change in Plasma 2-AAA Concentration From Baseline — -9.35; 7.02 ng/ml
Knee Osteoarthritis
Primary: Change in Visual Analog Pain Scale (VAS) Over Time — 1.5; 2.0; 3.0 Median improvement in VAS pain score
Chronic Rhinosinusitis
Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…
Décolleté Wrinkles
Primary: Percentage of Treated Subjects With Improvement in Lines and Wrinkles of the Décolleté at Day 90 — 62.2 percentage of subjects
Blepharitis
Primary: The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid. — 0.547; 0.122 Proportion cured
Chronic Obstructive Pulmonary Disease · Chronic Bronchitis
Primary: Safety of Ivacaftor - Number of Participants With Adverse Events — 19; 6; 7; 3 Participants